Lead Product(s): EVX-01
Therapeutic Area: Oncology Product Name: EVX-01
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
EVX-01, a novel personalized cancer neoepitope immunotherapy based on Evaxion’s PIONEER artificial intelligence (AI) technology is being developed for the treatment of patients with melanoma, non-small cell lung cancer (NSCLC) and bladder cancer.